免疫抑制状態の患者での免疫応答


Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease
 Dailey J, Kozhaya L, Dogan M, et al. 〔medRxiv. 2021 Jun 15〕(査読前)


Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany
 Jensen B, Luebke N, Feldt T, et al. 〔Lancet Reg Health Eur. 2021 Sep;8:100164〕(査読済み)


Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer
 Goshen-Lago T, Waldhorn I, Holland R, et al. 〔JAMA Oncol. 2021 Jul 8;e212675〕(査読済み)


Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients (Correspondence)
 Carr EJ, Wu M, Harvey R, et al. 〔Lancet. 2021 Sep 18;398(10305):1038-1041〕(査読済み)


Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis
 Yau K, Abe KT, Naimark D, et al. 〔JAMA Netw Open. 2021 Sep 1;4(9):e2123622〕(査読済み)


Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients (Correspondence)
 Kamar N, Abravanel F, Marion O, et al. 〔N Engl J Med. 2021 Aug 12;385(7):661-662〕(査読済み)


Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses (Research Letter)
 Benotmane I, Gautier G, Perrin P, et al. 〔JAMA. 2021 Jul 23;326(11):1063-1065〕(査読済み)


Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients (Correspondence)
 Hall VG, Ferreira VH, Ku T, et al. 〔N Engl J Med. 2021 Sep 23;385(13):1244-1246〕(査読済み)